Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease
- PMID: 12210229
- DOI: 10.1002/1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M
Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease
Abstract
There is a need for a reliable, molecular-based ante mortem diagnostic test for Alzheimer's disease (AD). In this study, we examined the use of two-dimensional protein electrophoresis for generating molecular barcodes which may be useful for the clinical differentiation of AD patients from normals. We compared cerebrospinal fluid samples taken from AD patients with confirmed post mortem pathology to comparable specimens from normal volunteers. Using canonical correlation analysis, a panel of nine molecular markers were identified which segregated diseased cases from normal controls. Using the scaled volume image analysis variable, a principal factor analysis was also used to distinguish normal from AD spinal fluid, based on molecular markers identified using a heuristic clustering algorithm. The use of panels of molecular markers derived from proteomic analysis may offer the best prospect for developing molecular diagnostic tests for complex neurodegenerative disorders such as AD.
Similar articles
-
Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease.Electrophoresis. 2002 Jul;23(14):2242-6. doi: 10.1002/1522-2683(200207)23:14<2242::AID-ELPS2242>3.0.CO;2-F. Electrophoresis. 2002. PMID: 12210228
-
Proteome studies of CSF in AD patients.Mech Ageing Dev. 2006 Feb;127(2):133-7. doi: 10.1016/j.mad.2005.09.021. Epub 2005 Nov 15. Mech Ageing Dev. 2006. PMID: 16293296
-
Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.Ann Neurol. 2007 Feb;61(2):120-9. doi: 10.1002/ana.21038. Ann Neurol. 2007. PMID: 17167789
-
Recent cerebrospinal fluid biomarker studies of Alzheimer's disease.Expert Rev Proteomics. 2010 Dec;7(6):919-29. doi: 10.1586/epr.10.75. Expert Rev Proteomics. 2010. PMID: 21142892 Review.
-
Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach.Curr Opin Mol Ther. 2005 Dec;7(6):557-64. Curr Opin Mol Ther. 2005. PMID: 16372405 Review.
Cited by
-
CSF proteomic analysis in patients with normal pressure hydrocephalus selected for the shunt: CSF biomarkers of response to surgical treatment.Neurol Sci. 2010 Jun;31(3):283-91. doi: 10.1007/s10072-009-0181-0. Epub 2009 Nov 21. Neurol Sci. 2010. PMID: 19936883
-
Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.PLoS One. 2013 May 20;8(5):e64314. doi: 10.1371/journal.pone.0064314. Print 2013. PLoS One. 2013. PMID: 23700471 Free PMC article.
-
Redox proteomics in some age-related neurodegenerative disorders or models thereof.NeuroRx. 2006 Jul;3(3):344-57. doi: 10.1016/j.nurx.2006.05.003. NeuroRx. 2006. PMID: 16815218 Free PMC article. Review.
-
Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.J Neurochem. 2005 Dec;95(5):1461-71. doi: 10.1111/j.1471-4159.2005.03478.x. J Neurochem. 2005. PMID: 16313519 Free PMC article.
-
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.Am J Pathol. 2008 Jul;173(1):130-43. doi: 10.2353/ajpath.2008.080045. Epub 2008 Jun 13. Am J Pathol. 2008. PMID: 18556781 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
